The Technical Analyst
Aprea Therapeutics Inc [APRE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Aprea Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.39% $5.35
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 29.05 mill |
| EPS: | -3.95 |
| P/E: | -1.350 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 5.43 mill |
| Avg Daily Volume: | 0.0337 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.350 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.23x |
| Company: PE -1.350 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$7.09 (32.57%) $1.742 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.72 - 5.98 ( +/- 11.72%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-28 | Hamill John P. | Buy | 3 365 | Common Stock |
| 2024-03-28 | Hamill John P. | Buy | 13 460 | Stock Options (Right to Buy) |
| 2024-03-28 | Gilad Oren | Buy | 6 725 | Common Stock |
| 2024-03-28 | Gilad Oren | Buy | 26 900 | Stock Options (Right to Buy) |
| 2024-03-13 | Hamill John P. | Buy | 1 010 | Common Stock |
| INSIDER POWER |
|---|
| 89.82 |
| Last 96 transactions |
| Buy: 13 026 874 | Sell: 1 205 176 |
Forecast:
16:00 - $5.35
Live Trading Signals (every 1 min)
Forecast
1: 15:03 - $5.35
Forecast 2: 15:53 - $5.30
Forecast 3: 16:00 - $5.35
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $5.35 (-8.39% ) |
| Volume | 0.0072 mill |
| Avg. Vol. | 0.0337 mill |
| % of Avg. Vol | 21.33 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For APRE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Latest Press Releases
2024-04-10 12:00:00 - Press Release
Aprea Therapeutics Announces Presentations On Its Next Generation Wee1 Inhibitor, Apr-1051, And A Novel Macrocyclic Atr Inhibitor, Atrn-119, At Aacr Annual Meeting 2024
Pre-clinical findings underscore the potential of apr-1051, a next-generation wee1 kinase inhibitor, to be a well-tolerated and effective treatment for cyclin e-overexpressing cancers
2024-03-26 07:45:00 - Press Release
Aprea Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides A Business Update
First-in-class macrocyclic atr inhibitor, atrn-119, on track to complete dose escalation and potentially generate human efficacy data in h2 2024
2024-03-14 07:48:00 - Press Release
Karolinska Development's Portfolio Company Aprea Therapeutics Receives Fda Ind Approval And Secures Funding Of Usd 34 Million
Stockholm, sweden, march 14, 2024. karolinska development ab (nasdaq stockholm: kdev) announces that its portfolio company aprea therapeutics has received fda approval of the company's ind application for the drug candidate apr-1051. aprea has also secured funding up to usd 34 million through a financing round led by sphera healthcare. with the approval and financing in place, the company will be able to start the first clinical study with apr-1051.
2024-03-11 08:30:00 - Press Release
Aprea Therapeutics Announces Private Placement Financing Of Up To $34.0 Million
Financing led by sphera healthcare with participation from new and existing healthcare-focused institutional investors
2024-03-11 08:29:00 - Press Release
Aprea Therapeutics Announces Fda Clearance Of Ind For Apr-1051, Its Next Generation Wee1 Kinase Inhibitor For Cyclin E Overexpressing Cancers
Company plans to initiate phase 1 acesot-1051 ( a multi- c enter e valuation of wee1 inhibitor in patients with advanced so lid t umors, apr- 1051 ) clinical trial evaluating, highly selective, oral wee1 inhibitor, for monotherapy treatment of cyclin e overexpressing cancers including breast and ovarian cancers
Latest News
2024-01-30 08:00:00 - GlobeNewsWire
Aprea Therapeutics to Present at DDR Inhibitors Summit 2024
DOYLESTOWN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will deliver a presentation at the 7 th DDR Inhibitors Summit, to take place January 30 to February 1, 2024 in Boston, MA.
2023-06-14 08:00:00 - GlobeNewsWire
Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference
DOYLESTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Maxim Virtual Healthcare Conference, being held online from June 20–June 22, 2023.
2023-05-30 08:30:00 - GlobeNewsWire
Aprea Therapeutics to Present at BIO International Convention
DOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview at the BIO International Convention, being held in Boston, Massachusetts from June 5-8, 2023.
2023-04-24 11:25:57 - Zacks Investment Research
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
Aprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
2023-04-04 13:42:32 - Zacks Investment Research
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-01-11 08:51:03 - PennyStocks
Best Penny Stocks To Buy? 4 To Watch In January 2023
4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-13 12:47:43 - PennyStocks
Why The Stock Market Is Down Today & 4 Penny Stocks To Watch
Red Hot Biotech Penny Stocks To Watch Right Now The post Why The Stock Market Is Down Today & 4 Penny Stocks To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-08 12:56:59 - InvestorPlace
Aprea Therapeutics (APRE) Stock Soars as Wedbush Sets $3 Price Target
Wedbush analyst Robert Driscoll just gave a huge upside target for APRE stock. Here's why this is significant for the biotech sector.
2022-01-14 11:35:15 - Zacks Investment Research
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2021-12-10 16:08:33 - PennyStocks
Got $5 to Spend on Penny Stocks? Check These 4 Out
Got $5 to spend on penny stocks? Take a look at these four for your watchlist The post Got $5 to Spend on Penny Stocks?